SEC Filing Summary: Pieris Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Pieris Pharmaceuticals, Inc. on May 16, 2019. The registrant is an emerging growth company incorporated in Nevada. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory disclosure rather than financial performance data.
Material Changes and Events
- Regulation FD Disclosure (Item 7.01): On May 16, 2019, the company released an abstract regarding its Phase 2a study of the drug candidate PRS-080.
- Event Context: The abstract was released for the 24th Congress of the European Hematology Association.
- Exhibit Reference: The abstract is furnished as Exhibit 99.1 and incorporated by reference.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the standard disclaimer that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of the Securities Act or Exchange Act, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the clinical data and conclusions presented in the Phase 2a study abstract for PRS-080 (Exhibit 99.1).
- Confirm the status of the 24th Congress of the European Hematology Association presentation.
- Review subsequent filings for any updates on the PRS-080 development program.